Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Specific PHGKB|Pharmacogenomics PHGKB|PHGKB

Last Posted: Apr 09, 2021
spot light Spotlight

Pharmacogenomics in the Era of Next Generation Sequencing - from Byte to Bedside.
Russell Laura E et al. Drug metabolism reviews 2021 1-79

we provide an update of the functional impacts of rare pharmacogenetic variability and how this information can be leveraged to improve pharmacogenetic guidance. Furthermore, we critically discuss the current status of implementation of pharmacogenetic testing across drug development and layers of care. We identify major gaps and provide perspectives on how these can be minimized to optimize the utilization of NGS data.

How pharmacogenomics enables precision approach to care
L Strazewski, AMA, March 2021

"What we learned is that almost everyone has at least one high-risk variant” that can affect response to medication, he said “About 20% of prescriptions in primary care fall into that category. About 50% of patients said they were more likely to take their medications, knowing that this information was being incorporated.”

CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice
DC Leon et al, Pharmacogenomics Journal, March 2021

We studied 157 patients on codeine. Based on CYP2D6 genotyping, 69 were classified as poor/intermediate and 88 as normal/ultrarapid CYP2D6 metabolizers. In a propensity-score adjusted model, poor/intermediate metabolizers had lower odds (OR?=?0.35, p?=?0.02) of achieving a pain response than normal/ultrarapid metabolizers. Using a score that includes CYP2D6 phenotype and clinical variables, we found that response rate was 38.5% among patients in the high, 17.3% in the intermediate, and 9.4% in the low-score groups, respectively (p?=?0.001).

Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial.
Papastergiou John et al. Clinical and translational science 2021

In this prospective, single-blind randomized controlled design, we evaluated the impact of pharmacogenomics guided versus standard antidepressant treatment of depression and anxiety, implemented in three large community pharmacies. Participants were 213 outpatients diagnosed with major depressive disorder and/or generalized anxiety disorder, randomized to receive pharmacogenomics guided (n = 105) or standard antidepressant treatment (n = 108).

news Latest News and Publications
Biochip-based approach for comprehensive pharmacogenetic testing. External Web Site Icon
Ikonnikova Anna Yu et al. Drug metabolism and personalized therapy 2021
Precision Population Medicine in Primary Care: The Sanford Chip Experience. External Web Site Icon
Christensen Kurt D et al. Frontiers in genetics 2021 12626845
The prediction of preeclampsia: the way forward. External Web Site Icon
Myatt Leslie et al. American journal of obstetrics and gynecology 2021
Comparing low-pass sequencing and genotyping for trait mapping in pharmacogenetics. External Web Site Icon
Wasik Kaja et al. BMC genomics 2021 22(1) 197
Genetic Risk Assessment for Atherosclerotic Cardiovascular Disease: A Guide for the General Cardiologist. External Web Site Icon
Belanger Matthew J et al. Cardiology in review 2021
Genomic markers associated with successful treatment of hypertension with lisinopril: A pilot study. External Web Site Icon
Flaten Hania K et al. International journal of clinical pharmacology and therapeutics 2021
Genotype-Guided Antiplatelet Therapy in Patients With Coronary Artery Disease. External Web Site Icon
Franchi Francesco et al. JACC. Cardiovascular interventions 2021
Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. External Web Site Icon
Climent Elisenda et al. Nutrition, metabolism, and cardiovascular diseases : NMCD 2021
Pharmacogenomics in Pain Management: A Review of Relevant Gene-Drug Associations and Clinical Considerations. External Web Site Icon
Brandl Emily et al. The Annals of pharmacotherapy 2021 10600280211003875
A Retrospective Analysis of Actionable Pharmacogenetic/genomic Biomarker Language in FDA Labels. External Web Site Icon
Yamazaki Shinji et al. Clinical and translational science 2021


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.